Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateTimeSourceHeadlineSymbolCompany
12/04/20247:30AMBusiness WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/27/20249:00AMBusiness WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/07/20248:22AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/07/20247:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/07/20247:00AMBusiness WireAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/06/20247:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/04/20249:00AMBusiness WireAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/17/20249:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/17/20249:00AMBusiness WireAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/15/20249:00AMBusiness WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/03/20243:06PMPR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/02/20246:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/02/20246:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/02/20246:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/25/20245:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/16/20245:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/09/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/28/20248:30AMBusiness WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/26/20246:49PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/12/20249:00AMBusiness WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/20247:14AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/20247:00AMBusiness WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/05/20249:00AMBusiness WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/02/20249:00AMBusiness WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/18/20247:00PMPR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/10/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/10/20247:00AMBusiness WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/09/20244:01PMBusiness WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/07/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX